PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 27, 2021Clinical Research in Cardiology49 citationsOpen Access

Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry

MPMarco ProiettiMVMarco VitoloSHStephanie L. Harrison

Structured PICO

Does early rhythm control reduce the composite of cardiovascular death, stroke, worsening heart failure, and acute coronary syndrome in patients with recently diagnosed atrial fibrillation compared to rate control?

P
Population
3,774 adults with atrial fibrillation diagnosed within 12 months, eligible for EAST-AFNET 4 criteria (age ≥75, prior stroke/TIA, or ≥2 other risk factors), mean age 69.8, 53.7% male, from a European multicenter registry (27 countries).
I
Intervention
Early rhythm control (antiarrhythmic drugs [Class Ia, Ic, III], electrical cardioversion, pharmacological cardioversion, or catheter ablation) at enrolment or discharge
C
Comparator
No rhythm control (rate control strategy using beta blockers, digoxin, or non-dihydropyridine calcium-channel blockers)
O
Outcome
Composite of cardiovascular death, any stroke, worsening heart failure, and acute coronary syndromecomposite

In a real-world European registry, early rhythm control for atrial fibrillation was associated with better quality of life but higher healthcare resource use, and did not significantly reduce major adverse cardiovascular events after multivariable adjustment compared to rate control.

Abstract

BACKGROUND: Use of rate/rhythm control is essential to control symptoms in patients with atrial fibrillation (AF). Recently, the EAST-AFNET 4 trial described how early rhythm control strategy was associated with a lower risk of adverse clinical outcomes. OBJECTIVES: The aim was to evaluate the real-world applicability and impact of an early rhythm control strategy in patients with AF. METHODS: Use of an early rhythm control strategy was assessed in a European cohort of AF patients derived from the EHRA-ESC EORP-AF General Long-Term Registry. Early rhythm control was defined as use of antiarrhythmic drugs or cardioversion/catheter ablation. The primary outcome included cardiovascular death, stroke, acute coronary syndrome, and worsening of heart failure. Quality of life and health-care resource usage were also assessed as outcomes. RESULTS: Among the 10,707 patients evaluated for eligibility to EAST-AFNET 4, a total of 3774 (34.0%) were included. Early rhythm control was associated with better quality of life, but with greater use of health-care resources. During follow-up, the primary outcome occurred less often in early rhythm control patients than in those with no rhythm control (13.6% vs. 18.5%, p < 0.001). In the multivariate adjusted Cox regression model, no significant difference was found between no rhythm control and early rhythm control, for the primary outcome. No difference in the primary outcome between early rhythm control and 'no rhythm control patients' adherent to Atrial fibrillation Better Care (ABC) pathway' was evident (p = 0.753) CONCLUSIONS: Use of an early rhythm control strategy was associated with a lower rate of major adverse events, but this difference was non-significant on multivariate analysis, being mediated by differences in baseline characteristics and clinical risk profile. Early rhythm control was associated with a higher use of health-care resources and risk of hospital admission, despite showing better quality of life.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Proietti et al. (2021) studied this question.

synapsesocial.com/papers/6a7cbe7ae7df423ee14c7c61https://doi.org/10.1007/s00392-021-01914-y
Ask AI
Helpful
Bookmark
Share
View Full Paper